Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

JFais May. 13 at 12:31 PM

$ABEO going from rare disease to PSMA T-cell engager (file IND 2H 27) ... didn't have that in my bingo card!

0 · Reply

alexpitti May. 13 at 12:26 PM

They got rid of eye program and now focused on the prostate, but no trial until 12 months from now. Good. Focus on the task at hand. $ABEO

0 · Reply

meatme May. 13 at 12:24 PM

$ABEO The first quarter of 2026 includes a single up-front payment of $7.0 million for in-licensing of the PSMA-SIR-T™ asset, now ABO-701. Excluding this transaction, R&D spending decreased by $7.4 million.

0 · Reply

Gymlover May. 13 at 12:21 PM

$ABEO please buckle your seats beasts we are about to fly.Have a nice trip

0 · Reply

Pharma3000 May. 13 at 12:17 PM

$ABEO Let's see when the short covering starts. I don't think any of them want to wait until Q2, since it's obvious that the price is headed in only one direction over the next 12 months.

0 · Reply

Marcel20 May. 13 at 12:14 PM

$ABEO 7 eow, 8 eom🔥

0 · Reply

commoncentsinvestor May. 13 at 12:14 PM

$ABEO Not often that a company beats Revenue estimates by 90%. Estimate was $4.57M Actual was $8.7M.

0 · Reply

Lodoli39 May. 13 at 12:14 PM

$ABEO let’s goooo

0 · Reply

Marcel20 May. 13 at 12:14 PM

$ABEO HUGE news!!!! Yes!!!!!🔥

0 · Reply

RDeneronow May. 13 at 12:11 PM

$ABEO The big news is Management is diligently working and Execution is Real !!! It will be a good year !!! Moving forward and Moving Up 📈 🚀 GLTA

0 · Reply

Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)

May 13, 2026, 7:30 AM EDT - 1 hour ago

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

May 11, 2026, 8:30 AM EDT - 2 days ago

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

May 4, 2026, 8:30 AM EDT - 9 days ago

Abeona Therapeutics® Announces Date of First Quarter Financial Results

May 1, 2026, 8:30 AM EDT - 12 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 7, 2026, 8:30 AM EDT - 5 weeks ago

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Apr 2, 2026, 8:30 AM EDT - 5 weeks ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

2026-03-17T21:40:20.000Z - 2 months ago

Abeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global

Mar 17, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics Earnings Call Transcript: Q4 2025

2026-03-17T12:05:19.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 17, 2026

ASO DOCU HITI HUYA LULU QFIN TME

2026-03-17T11:35:14.000Z - 2 months ago

Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year

Mar 17, 2026, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Abeona Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:41:57.000Z - 2 months ago

Abeona Therapeutics provides business update on momentum in Zevaskyn launch

Mar 9, 2026, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Mar 3, 2026, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

2025-12-31T12:35:26.000Z - 4 months ago

Abeona Therapeutics announces employee inducement grants

2025-12-15T12:36:04.000Z - 5 months ago

Abeona Therapeutics appoints Mohamad Tabrizi as CBO

Dec 15, 2025, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

2025-12-11T12:35:25.000Z - 5 months ago

Abeona Therapeutics announces new treatment center for Zevaskyn in Texas

Dec 11, 2025, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

2025-12-08T12:35:33.000Z - 5 months ago

Abeona Therapeutics announces first patient treatment with ZEVASKYN

Dec 8, 2025, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

2025-12-01T12:35:41.000Z - 5 months ago

Abeona Therapeutics reports employee inducement grants

Nov 13, 2025, 1:20 PM EST - 6 months ago

Abeona Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-12T19:20:27.000Z - 6 months ago

Abeona Therapeutics price target lowered to $19 from $20 at Stifel

Nov 12, 2025, 8:30 AM EST - 6 months ago

Abeona Therapeutics Earnings Call Transcript: Q3 2025

2025-11-12T12:36:04.000Z - 6 months ago

Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)

2025-11-12T12:35:51.000Z - 6 months ago

Abeona Therapeutics sees cash runway for over two years

Nov 12, 2025, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

2025-11-03T12:35:07.000Z - 6 months ago

Abeona Therapeutics announces employee inducement grants

2025-10-30T14:50:28.000Z - 6 months ago

Abeona Therapeutics announces permanent J-Code for ZEVASKYN

Oct 30, 2025, 10:45 AM EDT - 6 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

2025-10-20T12:47:35.000Z - 7 months ago

Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development

Oct 20, 2025, 8:30 AM EDT - 7 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

2025-10-13T11:35:17.000Z - 7 months ago

Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA

Oct 13, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 8, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Sep 9, 2025, 2:00 PM EDT - 8 months ago

Abeona Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:20 AM EDT - 8 months ago

Abeona Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 10:00 AM EDT - 10 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 10 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 10 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 4, 2025, 11:40 AM EDT - 1 year ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 8:46 AM EDT - 1 year ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q1 2025

May 14, 2025, 8:07 AM EDT - 1 year ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 29, 2025, 6:06 AM EDT - 1 year ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 1 year ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q4 2024

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Abeona Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Abeona Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Sep 19, 2024, 9:45 AM EDT - 1 year ago

Abeona Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 1:30 PM EDT - 1 year ago

Abeona Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 11, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 9, 2024, 9:45 AM EDT - 2 years ago

Abeona Therapeutics Transcript: Stifel Virtual Cell Therapy Forum

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

JFais May. 13 at 12:31 PM

$ABEO going from rare disease to PSMA T-cell engager (file IND 2H 27) ... didn't have that in my bingo card!

0 · Reply

alexpitti May. 13 at 12:26 PM

They got rid of eye program and now focused on the prostate, but no trial until 12 months from now. Good. Focus on the task at hand. $ABEO

0 · Reply

meatme May. 13 at 12:24 PM

0 · Reply

Gymlover May. 13 at 12:21 PM

$ABEO please buckle your seats beasts we are about to fly.Have a nice trip

0 · Reply

Pharma3000 May. 13 at 12:17 PM

$ABEO Let's see when the short covering starts. I don't think any of them want to wait until Q2, since it's obvious that the price is headed in only one direction over the next 12 months.

0 · Reply

Marcel20 May. 13 at 12:14 PM

$ABEO 7 eow, 8 eom🔥

0 · Reply

commoncentsinvestor May. 13 at 12:14 PM

$ABEO Not often that a company beats Revenue estimates by 90%. Estimate was $4.57M Actual was $8.7M.

0 · Reply

Lodoli39 May. 13 at 12:14 PM

$ABEO let’s goooo

0 · Reply

Marcel20 May. 13 at 12:14 PM

$ABEO HUGE news!!!! Yes!!!!!🔥

0 · Reply

RDeneronow May. 13 at 12:11 PM

$ABEO The big news is Management is diligently working and Execution is Real !!! It will be a good year !!! Moving forward and Moving Up 📈 🚀 GLTA

0 · Reply

TragicRain May. 13 at 12:06 PM

$ABEO - ssshhhh....(presses finger to Goo's lips)......the grown ups are making money.......

0 · Reply

Cautiousamphybian May. 13 at 12:05 PM

$ABEO $8.7M for 3 treatments completed = $2.9M per treatment. Can that be correct? They don't have any other revenue streams and 2025 revenue was banked in 2025.

1 · Reply

V4villanova May. 13 at 12:01 PM

$ABEO I will be surprised with the progress this company on multiple fronts if it stays independent. I have been with ABEO for a long time and hold a large position and see this earnings report as the inflection point where much higher share price is in our near future.

0 · Reply

stockinvestor102 May. 13 at 11:59 AM

$ABEO huge beat on revenue expectations

1 · Reply

Pharma3000 May. 13 at 11:59 AM

$ABEO Great News!!

0 · Reply

FitzCatalyst May. 13 at 11:58 AM

$ABEO dang. Bring back that $6.17 please

0 · Reply

creditgoo May. 13 at 11:57 AM

$ABEO and sell off

0 · Reply

Stock_Catcher May. 13 at 11:46 AM

$ABEO Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

0 · Reply

jamestrade07 May. 13 at 11:44 AM

$ABEO Sees that Q3 will be the breakeven point. A bit slower than what they initially projected, but still good enough to bring us to double digits later this year..

0 · Reply

alexpitti May. 13 at 11:42 AM

$ABEO for q2 it looks like 1 patient already treated 1 patient about to be treated and 6 scheduled biopies. so i'd guess around 6 treatments in q2. and then we scale in q3

2 · Reply

Abelixe May. 13 at 11:40 AM

$ABEO “95% of commercially insured U.S. lives” now covered. $168M cash is good for ABEO at this stage.

0 · Reply

StocktwitsEarnings May. 13 at 11:39 AM

$ABEO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.30 down -25.00% YoY • Reported revenue of $8.72M • Abeona Therapeutics Inc. expects current capital resources to fund operations for at least 12 months. The company plans to file an IND for ABO-701 and commence first-in-human studies in the second half of 2027.

0 · Reply

Market Cap	333.33M
Revenue (ttm)	5.82M
Net Income (ttm)	71.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,223.02%
Debt to Equity Ratio	0.13

Volume	1,282,300
Avg Vol	1,262,772
Day's Range	N/A - N/A
Shares Out	56.88M
Stochastic %K	46%
Beta	1.35
Analysts	Strong Sell
Price Target	$19.57